[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"induction-chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:induction-chemotherapy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100604004","prognostic-impacts-of-lipid-profile-and-bmi-in-adult-aml-100604004",false,"NCT07143877","Prognostic Impacts of Lipid Profile and BMI in Adult AML","Prognostic Impacts of Lipid Profile and Body Mass Index in Adult Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy","AML\u002FBMI","Inclusion Criteria:\n\n* Adult patients (≥18yearsold) newly diagnosed with AML.\n* Patients eligible for intensive induction chemotherapy.\n* Patients who have given informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with secondary or relapsed AML.\n* Patients currently using lipid-lowering medications (e.g., statins).\n* Patients with known endocrine or metabolic disorders affecting BMI or lipid profile (e.g., uncontrolled diabetes, hypothyroidism, Cushing's syndrome).\n* Pregnant or lactating women.\n* Patients unwilling or unable to complete the study protocol.\n* Patients with M3 subtype of AML.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","35 Days","OBSERVATIONAL","The goal of this observational study is to evaluate the changes in lipid profile parameters (total cholesterol, triglycerides, HDL-C, and LDL-C) in adult AML patients before and after intensive induction chemotherapy. The main questions it aims to answer are:\n\n* Are there correlations between metabolic changes (in lipid profile and BMI) and treatment outcomes, including remission status and incidence of chemotherapy-related complications?\n* Can the baseline lipid profile and BMI serve as prognostic markers for response to induction chemotherapy.?\n\nParticipants will be observed before and after induction chemotherapy regarding their lipid profile, and BMI, observing any correlations between the different results with any complications, and with remission status.",[26,27,28,29],"AML (Acute Myeloid Leukemia)","BMI","Lipid Profile","Induction Chemotherapy",[31,27,32,33,34],"AML","Lipid profile","Adult","Induction chemotherapy","NOT_YET_RECRUITING","2025-08-23",{"date":38,"type":39},"2025-08-27","ACTUAL",{"date":41,"type":21},"2025-11-15",{"date":43,"type":21},"2027-03-15",{"name":45,"class":46},"Assiut University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100523270","phase-1-induction-toripalimab-and-chemotherapy-in-locally-advanced-cervical-cancer-100523270","NCT06093438","Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer","Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Patients With High Risk of Recurrence: A Prospective, Single-Arm, Phase II Trial","Inclusion Criteria:\n\n1. Untreated locally advanced cervical cancer patients with clear pathological diagnosis\n2. 2019 FIGO stage IIIB-IVA. For patients with stage IIIC disease, the short diameter of their metastatic lymph nodes should ≥1.5cm\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n4. Life expectancy \\> 6 months\n5. Able to tolerate concurrent chemoradiotherapy assessed by researches\n6. No obvious active bleeding;\n7. Adequate hematological, renal and hepatic functions:\n8. No concomitant malignancies\n9. Female subjects of childbearing potential should have a negative pregnancy test and must take effective and reliable contraceptive measures during the clinical trial period;\n10. Voluntarily-signed informed consent.\n\nExclusion Criteria:\n\n1. Concomitant other malignancies;\n2. Patients with metastatic or recurrent disease;\n3. Patients received any form of treatment before enrollment;\n4. Severe concomitant chronic diseases (diabetes, hypertension, etc.) or acute infections;\n5. Impaired hematological, renal or hepatic functions:\n\n   1. Hemoglobin \\\u003C 9.0 g\u002Fdl\n   2. Neutrophils \\\u003C 2000 cells\u002Fμl; Leukocytes \\\u003C 4 × 109\u002FL\n   3. Platelets \\> 100 × 109\u002FL\n   4. Serum ALT\u002FAST \\> 2.5×UNL\n   5. Serum Total bilirubin \\> 1.5× UNL\n\n   g. Serum urea nitrogen (BUN) \\> 1.5 × upper normal limit (UNL) h. Serum creatinine (Cr) \\> 1.5 × upper normal limit (UNL)\n6. Patients with obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency or severe heart valve disease;\n7. Patients with uncontrolled mental diseases;\n8. Pregnant or lactating woman;\n9. Participating in other clinical trials;\n10. Anyone considered not suitable for enrollment by principal investigator;","FEMALE","75 Years",{"count":58,"type":21},20,"INTERVENTIONAL",[61,62],"PHASE1","PHASE2","To explore the efficacy of incorporating neoadjuvant immunotherapy into neoadjuvant chemotherapy in locally advanced cervical cancer patients with high risk of recurrence.",[65,29,66],"Cervical Cancer","Immunotherapy",[68,69,70,71],"cervical cancer","immunotherapy","neoadjuvant chemotherapy","chemoradiation","RECRUITING","2025-03-06",{"date":75,"type":39},"2025-03-11",{"date":77,"type":39},"2023-11-01",{"date":79,"type":21},"2026-07-01",{"name":81,"class":46},"Tianjin Medical University Cancer Institute and Hospital",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":59,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":47},"100469819","phase-2-envafolimab-plus-chemoradiotherapy-for-locally-advanced-npc-a-prospective-single-armed-phase-ii-trial-100469819","NCT05397769","Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.","Envafolimab Plus Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma, a Prospective, Single Armed Phase II Trial.","Inclusion Criteria:\n\n* ECOG 0-1\n* histologically confirmed non-keratinizing carcinoma (WHO type II or III) of nasal pharynx\n* stage III-IVa （AJCC\u002FUICC 8th ）, untreated NPC patients\n* NE≥ 1.5×10E9\u002FL, HGB ≥ 100g\u002FL and PLT ≥100×10E9\u002FL\n* ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN\n* creatinine\\\u003C1.5×ULN\n\nExclusion Criteria:\n\n* recurrent or metastatic NPC patients\n* histologically confirmed keratinizing carcinoma (WHO type I) of nasal pharynx\n* already received radiation or chemotherapy\n* pregnant or lactating women, or women of childbearing age without birth control\n* HIV (+)\n* had other cancers before\n* used immune checkpoint inhibitor(CTLA-4、PD-1、PD-L1 etc.) before\n* complications requiring long-term treatment with immunosuppressive drugs or systemic or local use of corticosteroids with immunosuppressive dose\n* with immune deficiency diseases, or a history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma in childhood who have completely relieved and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators cannot be included)\n* use of massive dose of glucocorticoids within 4 weeks before enrollment\n* laboratory test values do not meet relevant standards within 7 days before enrollment\n* significantly lower functions of heart, liver, lung, kidney and bone marrow\n* serious or uncontrolled medical diseases or infections\n* participating other clinical trial in the same time\n* HBsAg (+) and HBV DNA \\>1×10E3 copiers \u002FmL\n* HCV (+) unless HCV RNA PCR(-)\n* with any other treatment contraindications","65 Years",{"count":91,"type":21},36,[62],"Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy. After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be given by IMRT, under the dose of GTVnx 68-70Gy\u002F30-33f, 5d\u002Fw,6-7w, during which, every patient would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease progression or intolerance of treatment. . We aim to evaluate the three years progression free survival of these patients by the combination of Envafolimab with curative chemoradiotherapy.",[95,96,29,97],"Locally Advanced Nasopharyngeal Carcinoma","Envafolimab","PD-L1","2022-08-09",{"date":100,"type":39},"2022-08-10",{"date":102,"type":39},"2022-06-08",{"date":104,"type":21},"2026-12-31",{"name":106,"class":46},"Sun Yat-sen University"]